Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Single Rapid Test Detects Known and Unknown Pathogens

By LabMedica International staff writers
Posted on 10 Nov 2014
Diagnostic technology developed for rapid detection of pathogens in the wounds of soldiers has been licensed to a private company that intends to use it to create new medical laboratory tests.

The Lawrence Livermore Microbial Detection Array (LLMDA) is designed to improve on two pathogen identification techniques: Polymerase chain reaction (PCR) analysis and DNA sequencing. More...
PCR diagnostic techniques can process no more than 50 DNA signatures at one time and the likelihood of discovering new species are low with PCR. The new technology is capable of identifying thousands of bacteria and viruses in a single test.

Scientists at the Lawrence Livermore National Laboratory (LLNL; Livermore, CA, USA) developed the LLMDA. The process begins by purifying DNA or ribonucleic acid (RNA) from a blood or stool sample. The purified DNA or RNA is labeled with a fluorescent dye, and then pipetted onto the microarray which sits on top of an incubator heated to 42 °C. The microarray contains nearly 400,000 probes arranged in a checkerboard pattern on a 2.5 × 7.5-cm glass slide. Scientists examine these probes with a fluorescent scanner and analysis software. The microarray’s checkerboard has several dozen squares for each of the thousands of organisms sequenced to date. That allows it to simultaneously examine multiple regions from each organism.

From a study that evaluated 124 wound samples from 44 soldiers injured in Iraq and Afghanistan using LLDMA, the scientists found certain bacteria, such as Pseudomonas species and Acinetobacter baumannii, which are common hospital-related infections, to be associated with wounds that did not heal successfully. Bacteria often related to the gastrointestinal system, such as Escherichia coli and Bacteroides species, were also often found in wounds that did heal successfully. The test was able to detect within 24 hours any virus or bacteria that has been sequenced and included among the array's probes.

The LLNL scientists are already building on the capacity of this microbial array. They are currently testing a next-generation LLMDA that contains 2.1 million probes representing about 178,000 sequences from 5,700 viruses and 785,000 sequences from thousands of bacteria. The new version also includes about 237,000 sequences from hundreds of fungi and about 202,000 sequences from 75 protozoa. Lawrence Livermore National Laboratory has licensed its microbial detection array technology to MOgene LC (St. Louis, MO, USA).

Related Links:
Lawrence Livermore National Laboratory
MOgene LC 



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Specimen Radiography System
TrueView 200 Pro
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Illustration of a cross-section of a blood vessel with red blood cells, white blood cells, and fragments of DNA (Photo Courtesy of UC San Diego/Adobe Firefly)

Microbial DNA Signature in Blood Plasma Differentiates Two Liver Cancer Types

Determining whether a cancerous tumor originated in a given location or spread from another organ is critical for guiding diagnosis and treatment decisions. When the primary tumor site cannot be identified,... Read more

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.